181 related articles for article (PubMed ID: 37452618)
1. An assessment of the effects of neurokinin
Andrews PLR; Golding JF; Sanger GJ
Br J Clin Pharmacol; 2023 Dec; 89(12):3468-3490. PubMed ID: 37452618
[TBL] [Abstract][Full Text] [Related]
2. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
4. [Prophylaxis of chemotherapy-induced vomiting and nausea].
Tóth J; Szántó J
Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting.
Santana TA; Trufelli DC; Matos LL; Cruz FM; Del Giglio A
Support Care Cancer; 2015 Jan; 23(1):213-22. PubMed ID: 25145507
[TBL] [Abstract][Full Text] [Related]
6. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
[TBL] [Abstract][Full Text] [Related]
7. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
8. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.
Hesketh PJ
Support Care Cancer; 2001 Jul; 9(5):350-4. PubMed ID: 11497388
[TBL] [Abstract][Full Text] [Related]
9. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting.
Diemunsch P; Joshi GP; Brichant JF
Br J Anaesth; 2009 Jul; 103(1):7-13. PubMed ID: 19454547
[TBL] [Abstract][Full Text] [Related]
11. A re-consideration of neural/receptor mechanisms in chemotherapy-induced nausea and vomiting: current scenario and future perspective.
Ullah I; Ayaz M
Pharmacol Rep; 2023 Oct; 75(5):1126-1137. PubMed ID: 37584820
[TBL] [Abstract][Full Text] [Related]
12. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.
Jordan K; Blättermann L; Hinke A; Müller-Tidow C; Jahn F
Support Care Cancer; 2018 Jan; 26(1):21-32. PubMed ID: 28861627
[TBL] [Abstract][Full Text] [Related]
13. Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.
Darmani NA; Wang Y; Abad J; Ray AP; Thrush GR; Ramirez J
Brain Res; 2008 Jun; 1214():58-72. PubMed ID: 18471804
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends.
Gupta K; Walton R; Kataria SP
Cancer Treat Res Commun; 2021; 26():100278. PubMed ID: 33360668
[TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis of nausea and vomiting after medical cancer treatment : Guidelines on supportive treatment-Part II].
Link H
Urologie; 2022 Jun; 61(6):667-680. PubMed ID: 35925083
[TBL] [Abstract][Full Text] [Related]
16. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yuan DM; Li Q; Zhang Q; Xiao XW; Yao YW; Zhang Y; Lv YL; Liu HB; Lv TF; Song Y
Asian Pac J Cancer Prev; 2016; 17(4):1661-75. PubMed ID: 27221836
[TBL] [Abstract][Full Text] [Related]
18. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
19. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
20. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
